The role of adjunctive exenatide therapy in pediatric type 1 diabetes

Vandana S. Raman, Kimberly J. Mason, Luisa M. Rodriguez, Krishnavathana Hassan, Xiaoying Yu, Lisa Bomgaars, Rubina A. Heptulla

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

OBJECTIVE- Exenatide improves postprandial glycemic excursions in type 2 diabetes. Exenatide could benefit type 1 diabetes as well. We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS- Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide. Two doses of exenatide (1.25 and 2.5 μg) were compared with insulin monotherapy. Prandial insulin dose was reduced by 20%. Gastric emptying and hormones were analyzed for 300 min postmeal. RESULTS- Treatment with both doses of exenatide versus insulin monotherapy significantly reduced glucose excursions over 300 min (P < 0.0001). Exenatide administration failed to suppress glucagon but delayed gastric emptying (P < 0.004). CONCLUSIONS- Adjunctive exenatide therapy reduces postprandial hyperglycemia in adolescents with type 1 diabetes. This reduction in glucose excursion occurs despite reduction in insulin dose. We suggest that exenatide has therapeutic potential as adjunctive therapy in type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)1294-1296
Number of pages3
JournalDiabetes Care
Volume33
Issue number6
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Type 1 Diabetes Mellitus
Pediatrics
Insulin
Therapeutics
Gastric Emptying
Glucose
exenatide
Glucagon
Hyperglycemia
Type 2 Diabetes Mellitus
Meals
Research Design
Hormones

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Raman, V. S., Mason, K. J., Rodriguez, L. M., Hassan, K., Yu, X., Bomgaars, L., & Heptulla, R. A. (2010). The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care, 33(6), 1294-1296. https://doi.org/10.2337/dc09-1959

The role of adjunctive exenatide therapy in pediatric type 1 diabetes. / Raman, Vandana S.; Mason, Kimberly J.; Rodriguez, Luisa M.; Hassan, Krishnavathana; Yu, Xiaoying; Bomgaars, Lisa; Heptulla, Rubina A.

In: Diabetes Care, Vol. 33, No. 6, 06.2010, p. 1294-1296.

Research output: Contribution to journalArticle

Raman, VS, Mason, KJ, Rodriguez, LM, Hassan, K, Yu, X, Bomgaars, L & Heptulla, RA 2010, 'The role of adjunctive exenatide therapy in pediatric type 1 diabetes', Diabetes Care, vol. 33, no. 6, pp. 1294-1296. https://doi.org/10.2337/dc09-1959
Raman VS, Mason KJ, Rodriguez LM, Hassan K, Yu X, Bomgaars L et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010 Jun;33(6):1294-1296. https://doi.org/10.2337/dc09-1959
Raman, Vandana S. ; Mason, Kimberly J. ; Rodriguez, Luisa M. ; Hassan, Krishnavathana ; Yu, Xiaoying ; Bomgaars, Lisa ; Heptulla, Rubina A. / The role of adjunctive exenatide therapy in pediatric type 1 diabetes. In: Diabetes Care. 2010 ; Vol. 33, No. 6. pp. 1294-1296.
@article{38cb2c9019874b6fa714107a7f81f54e,
title = "The role of adjunctive exenatide therapy in pediatric type 1 diabetes",
abstract = "OBJECTIVE- Exenatide improves postprandial glycemic excursions in type 2 diabetes. Exenatide could benefit type 1 diabetes as well. We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS- Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide. Two doses of exenatide (1.25 and 2.5 μg) were compared with insulin monotherapy. Prandial insulin dose was reduced by 20{\%}. Gastric emptying and hormones were analyzed for 300 min postmeal. RESULTS- Treatment with both doses of exenatide versus insulin monotherapy significantly reduced glucose excursions over 300 min (P < 0.0001). Exenatide administration failed to suppress glucagon but delayed gastric emptying (P < 0.004). CONCLUSIONS- Adjunctive exenatide therapy reduces postprandial hyperglycemia in adolescents with type 1 diabetes. This reduction in glucose excursion occurs despite reduction in insulin dose. We suggest that exenatide has therapeutic potential as adjunctive therapy in type 1 diabetes.",
author = "Raman, {Vandana S.} and Mason, {Kimberly J.} and Rodriguez, {Luisa M.} and Krishnavathana Hassan and Xiaoying Yu and Lisa Bomgaars and Heptulla, {Rubina A.}",
year = "2010",
month = "6",
doi = "10.2337/dc09-1959",
language = "English (US)",
volume = "33",
pages = "1294--1296",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - The role of adjunctive exenatide therapy in pediatric type 1 diabetes

AU - Raman, Vandana S.

AU - Mason, Kimberly J.

AU - Rodriguez, Luisa M.

AU - Hassan, Krishnavathana

AU - Yu, Xiaoying

AU - Bomgaars, Lisa

AU - Heptulla, Rubina A.

PY - 2010/6

Y1 - 2010/6

N2 - OBJECTIVE- Exenatide improves postprandial glycemic excursions in type 2 diabetes. Exenatide could benefit type 1 diabetes as well. We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS- Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide. Two doses of exenatide (1.25 and 2.5 μg) were compared with insulin monotherapy. Prandial insulin dose was reduced by 20%. Gastric emptying and hormones were analyzed for 300 min postmeal. RESULTS- Treatment with both doses of exenatide versus insulin monotherapy significantly reduced glucose excursions over 300 min (P < 0.0001). Exenatide administration failed to suppress glucagon but delayed gastric emptying (P < 0.004). CONCLUSIONS- Adjunctive exenatide therapy reduces postprandial hyperglycemia in adolescents with type 1 diabetes. This reduction in glucose excursion occurs despite reduction in insulin dose. We suggest that exenatide has therapeutic potential as adjunctive therapy in type 1 diabetes.

AB - OBJECTIVE- Exenatide improves postprandial glycemic excursions in type 2 diabetes. Exenatide could benefit type 1 diabetes as well. We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes. RESEARCH DESIGN AND METHODS- Eight subjects completed a three-part double-blinded randomized controlled study of premeal exenatide. Two doses of exenatide (1.25 and 2.5 μg) were compared with insulin monotherapy. Prandial insulin dose was reduced by 20%. Gastric emptying and hormones were analyzed for 300 min postmeal. RESULTS- Treatment with both doses of exenatide versus insulin monotherapy significantly reduced glucose excursions over 300 min (P < 0.0001). Exenatide administration failed to suppress glucagon but delayed gastric emptying (P < 0.004). CONCLUSIONS- Adjunctive exenatide therapy reduces postprandial hyperglycemia in adolescents with type 1 diabetes. This reduction in glucose excursion occurs despite reduction in insulin dose. We suggest that exenatide has therapeutic potential as adjunctive therapy in type 1 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=77956074558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956074558&partnerID=8YFLogxK

U2 - 10.2337/dc09-1959

DO - 10.2337/dc09-1959

M3 - Article

C2 - 20332358

AN - SCOPUS:77956074558

VL - 33

SP - 1294

EP - 1296

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 6

ER -